U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C35H34ClN7O3S2
Molecular Weight 700.273
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-03715455

SMILES

CC(C)(C)C1=NN(C(NC(=O)NCC2=CC=CC=C2SC3=CN4C(C=C3)=NN=C4C5=CC=CC=C5SCCO)=C1)C6=CC=C(O)C(Cl)=C6

InChI

InChIKey=VGEXRDWWPSGZDH-UHFFFAOYSA-N
InChI=1S/C35H34ClN7O3S2/c1-35(2,3)30-19-32(43(41-30)23-12-14-27(45)26(36)18-23)38-34(46)37-20-22-8-4-6-10-28(22)48-24-13-15-31-39-40-33(42(31)21-24)25-9-5-7-11-29(25)47-17-16-44/h4-15,18-19,21,44-45H,16-17,20H2,1-3H3,(H2,37,38,46)

HIDE SMILES / InChI

Molecular Formula C35H34ClN7O3S2
Molecular Weight 700.273
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

PF-03715455 is a potent p38 inhibitor, showing some selectivity for p38-alpha over p38-beta. PF-03715455 inhibited IL-6, MCP-1, MIP1β, CC16 and CRP levels in plasma of healthy subjects. PF-03715455 was optimized for delivery by inhalation. PF-03715455 substantially reduced tobacco-smoke--induced lung neutrophilia and inflammatory damage to the lungs. PF-03715455 had been in phase II clinical trial for the treatment of asthma and phase I clinical trial for the treatment of chronic obstructive pulmonary disease. However, these investigations were discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.
2011 Nov 24
Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects.
2015 Oct
Patents

Sample Use Guides

680 ug b.i.d.
Route of Administration: Respiratory
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:41:35 UTC 2023
Edited
by admin
on Sat Dec 16 05:41:35 UTC 2023
Record UNII
0TJ631J0KP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-03715455
Common Name English
PF-3715455
Common Name English
UREA, N-(1-(3-CHLORO-4-HYDROXYPHENYL)-3-(1,1-DIMETHYLETHYL)-1H-PYRAZOL-5-YL)-N'-((2-((3-(2-((2-HYDROXYETHYL)THIO)PHENYL)-1,2,4-TRIAZOLO(4,3-A)PYRIDIN-6-YL)THIO)PHENYL)METHYL)-
Systematic Name English
Code System Code Type Description
CAS
1056164-52-3
Created by admin on Sat Dec 16 05:41:35 UTC 2023 , Edited by admin on Sat Dec 16 05:41:35 UTC 2023
PRIMARY
ChEMBL
CHEMBL1938400
Created by admin on Sat Dec 16 05:41:35 UTC 2023 , Edited by admin on Sat Dec 16 05:41:35 UTC 2023
PRIMARY
EPA CompTox
DTXSID70147214
Created by admin on Sat Dec 16 05:41:35 UTC 2023 , Edited by admin on Sat Dec 16 05:41:35 UTC 2023
PRIMARY
DRUG BANK
DB12138
Created by admin on Sat Dec 16 05:41:35 UTC 2023 , Edited by admin on Sat Dec 16 05:41:35 UTC 2023
PRIMARY
PUBCHEM
11714580
Created by admin on Sat Dec 16 05:41:35 UTC 2023 , Edited by admin on Sat Dec 16 05:41:35 UTC 2023
PRIMARY
FDA UNII
0TJ631J0KP
Created by admin on Sat Dec 16 05:41:35 UTC 2023 , Edited by admin on Sat Dec 16 05:41:35 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY